Precision BioSciences Inc Total Liabilities
Precision BioSciences Inc total liabilities. Based on the latest financial reports, Precision BioSciences Inc (DTIL) has total liabilities worth $80.63 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Precision BioSciences Inc (DTIL) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Precision BioSciences Inc (2016–2025)
Total liabilities of Precision BioSciences Inc from 2016 to 2025. This chart illustrates how Precision BioSciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore DTIL long-term investment intensity to see how much of total assets are deployed in long-term investments.
Precision BioSciences Inc Competitors by Total Liabilities
The table below lists competitors of Precision BioSciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Apator S.A.
WAR:APT
|
Poland | zł389.11 Million |
|
Kross Ltd
NSE:KROSS
|
India | Rs1.49 Billion |
|
Nanhua Instruments Co Ltd
SHE:300417
|
China | CN¥89.85 Million |
|
QDRO Acquisition Corp. Class A Ordinary Shares
NASDAQ:QADR
|
USA | $8.41 Million |
|
New Fortress Energy LLC
NASDAQ:NFE
|
USA | $10.25 Billion |
|
Currenc Group Inc. Ordinary Shares
NASDAQ:CURR
|
USA | $95.41 Million |
|
A Paradise Acquisition Corp.
NASDAQ:APAD
|
USA | $8.47 Million |
|
Henan BCCY Environmental Energy Co. Ltd
SHE:300614
|
China | CN¥896.06 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Precision BioSciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Precision BioSciences Inc's balance sheet.
Liquidity & Leverage Metrics
Precision BioSciences Inc Total Liabilities Ratios Explained
Precision BioSciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Precision BioSciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Precision BioSciences Inc (2016–2025)
The table below shows the annual total liabilities of Precision BioSciences Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $62.17 Million | -22.29% |
| 2024-12-31 | $80.00 Million | -43.23% |
| 2023-12-31 | $140.92 Million | -20.71% |
| 2022-12-31 | $177.74 Million | +47.71% |
| 2021-12-31 | $120.33 Million | +13.81% |
| 2020-12-31 | $105.73 Million | +9.09% |
| 2019-12-31 | $96.92 Million | -1.74% |
| 2018-12-31 | $98.64 Million | -0.41% |
| 2017-12-31 | $99.05 Million | -3.99% |
| 2016-12-31 | $103.16 Million | -- |
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalent… Read more